Back to T-B+ Severe Combined Immunodeficiency Due to Gamma Chain Deficiency

T-B+ Severe Combined Immunodeficiency Due to Gamma Chain Deficiency — Clinical Trials

MONDO:00103152 active·2 recruitingLast updated: Mar 16, 2026, 1:21 AM

Trial Landscape

T-B+ Severe Combined Immunodeficiency Due to Gamma Chain Deficiency has an emerging clinical trial program, driven by drug treatment and biological therapy.

Recruiting

Active Trials

By Approach

Drug Treatment1

Biological Therapy1

By Phase

Phase 1

Phase 2

Sponsor Types

Academic/Other2

Trial Locations

China1 trial

United Kingdom1 trial

Trials often recruit across multiple countries, so totals exceed the trial count.

2 Trials

Phase 1RecruitingGene Therapy

NCT03217617

SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) Injection

Sponsor:Shenzhen Geno-Immune Medical Institute

ChinaStarted: Jun 2024Est. completion: Dec 2027Updated: Sep 2025

Phase 1RecruitingGene Therapy

NCT03601286

Lentiviral Gene Therapy for X-linked Severe Combined Immunodeficiency

Sponsor:Great Ormond Street Hospital for Children NHS Foundation Trust

United KingdomStarted: Dec 2018Est. completion: Aug 2026Updated: Oct 2023

Last updated over 18 months ago

Stay informed about clinical trials for T-B+ Severe Combined Immunodeficiency Due to Gamma Chain Deficiency.

Follow this disease to get updates when trials open, close, or change status.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.

Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.

Last sync: March 16, 2026 at 1:21 AM